Ray, Kausik K.
Nicholls, Stephen J.
Ginsberg, Henry D
Johansson, Jan O.
Kalantar-Zadeh, Kamyar
Kulikowski, Ewelina
Toth, Peter P.
Wong, Norman
Cummings, Jeffrey L.
Sweeney, Michael
Schwartz, Gregory G.
Funding for this research was provided by:
Shire
Takeda Pharmaceutical Company
Sunovion
Merck Sharp and Dohme
NIHR Imperial Biomedical Research Centre
AbbVie
Pfizer
Medicines Company
Genentech
Hospira
Roche
Novo Nordisk
Sanofi
Sandoz
Amgen
Amarin Corporation
Abbott Laboratories
This article is maintained by: Elsevier
Article Title: Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial
Journal Title: American Heart Journal
CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.ahj.2019.08.001
Content Type: article
Copyright: Crown Copyright © 2019 Published by Elsevier Inc. All rights reserved.